Hayes, R., LeLacheur, R., Dumont, I., Couerbe, P., Safavi, A., Islam, R., Pattison, C., Cape, S., Rocci, M., Briscoe, C., Cojocaru, L., Groeber, E., Silvestro, L., Bravo, J., Shoup, R., Verville, M., Zimmer, J., Caturla, M. C., Khadang, A., Bourdage, J., Hughes, N., Fatmi, S., Di Donato, L., Sheldon, C., Keyhani, A., Satterwhite, C., Yu, M., Fiscella, M., Hulse, J., Lin, Z. (., Garofolo, W., Savoie, N., Xiao, Y. Q., Kurylak, K., Harris, S., Saxena, M., Buonarati, M., Lévesque, A., Boudreau, N., Lin, J., Khan, M. U., Ray, G., Liu, Y., Xu, A., Soni, G., Ward, I., Kingsley, C., Ritzén, H., Tabler, E., Nicholson, B., Bennett, P., van de Merbel, N., Karnik, S., Bouhajib, M., Wieling, J., Mulvana, D., Ingelse, B., Allen, M., Malone, M., & Fang, X. (2016). 9th GCC closed forum: CAPA in regulated bioanalysis; method robustness, biosimilars, preclinical method validation, endogenous biomarkers, whole blood stability, regulatory audit experiences and electronic laboratory notebooks. Bioanalysis, 8, 487–495. http://access.bl.uk/ark:/81055/vdc_100137427533.0x00000c